Systemic bias in the medical literature on androgen deprivation therapy and its implication to clinical practice

International Journal of Clinical Practice

Volumn 66, Issue 12, 2012, Pages 1189-1196

  Phillips, J L ^a   Wassersug, R J ^a,b   McLeod, D L ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GONADORELIN AGONIST;

ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CLINICAL PRACTICE; DEPRESSION; DRUG INDUSTRY; DRUG SAFETY; FATIGUE; HOT FLUSH; HUMAN; INFERTILITY; MEDICAL LITERATURE; PEER REVIEW; PRIORITY JOURNAL; PROSTATE CANCER; SOCIAL PSYCHOLOGY; SYSTEMATIC ERROR; SYSTEMATIC REVIEW;

BIAS (EPIDEMIOLOGY); CONFLICT OF INTEREST; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PERIODICALS AS TOPIC; PROSTATIC NEOPLASMS; PUBLICATION BIAS;

EID: 84869484925     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/ijcp.12025     Document Type: Article

References (57)

1. Schulman C, Irani J, Morote J, et al., Androgen-deprivation therapy in prostate cancer: a European expert panel review. Eur Urol Suppl 2010; 9: 675-91.
2. Langley RE, Price P, Abel PD,. Letter to the editor re: Schulman C, Irani J, Morote J et al. Androgen-deprivation therapy in prostate cancer: a European expert panel review. Eur Urol 2011; 59: e24-5.
3. Smith MR,. Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007; 14: 247-54.
4. Bagrodia A, DiBlasio CJ, Wake RW, Derweesh IH,. Adverse effects of androgen deprivation therapy in prostate cancer: current management issues. Indian J Urol 2009; 25: 169-76.
5. United States of America Food and Drug Administration. GnRH agonists: label change increased risk of diabetes and cardiovascular disease (update). 2010. Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm230359.htm(accessed February 2012)
6. Jefferies ER, Thurairaja R, Persad RA, Rajani R, Phull JS, Bahl A,. Don't think once, think twice! The cardiovascular effects of androgen deprivation therapy. BJU Int 2011; 107: 1023-8.
7. Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW,. The ADT Survivorship Working Group. Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. J Sex Med 2010; 7: 2996-3010.
8. Saini A, Berruti A, Cracco C, Sguazzotti E, Porpiglia F, Russo L, et al. Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy. Urol Oncol 2011;Epub ahead of print. Jul 29 2011.
9. Nguyen PL, Je Y, Schutz FA, et al., Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011; 306: 2359-2366.
10. Timilshina N, Breunis H, Alibhai S,. Impact of androgen deprivation therapy on depressive symptoms in men with nonmetastatic prostate cancer. Cancer 2011; 118: 1940-5.
11. da Silva FC,. Intermittent hormonal therapy for prostate cancer. Curr Opin Urol 2011; 21: 248-251.
12. Scholz MC, Lam RY, Strum SB, et al., Primary intermittent androgen deprivation as initial therapy for men with newly diagnosed prostate cancer. Clin Genitourin Cancer 2011; 9: 89-94.
13. Buchan NC, Goldenberg SL,. Intermittent androgen suppression for prostate cancer. Nat Rev Urol 2010; 7: 552-560.
14. Norman G, Dean ME, Langley RE, et al., Parenteral oestrogen in the treatment of prostate cancer: a systematic review. Br J Cancer 2008; 98: 697-707.
15. Langley RE, Godsland IF, Kynaston H, et al., Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int 2008; 102: 442-5.
16. Ockrim JL, Lalani E, Kakkar AK, Abel PD,. Transdermal estradiol therapy for prostate cancer reduces thrombophilic activation and protects against thromboembolism. J Urol 2005; 174: 527-33.
17. Walker L, Tran S, Wassersug RJ, Thomas B, Robinson J,. Patients and partners lack knowledge of androgen deprivation therapy side effects. Urol Oncol 2012; Epub ahead of print. Jan 25 2012.
18. Cushman MA, Phillips JL, Wassersug RJ,. The language of emasculation: implications to cancer patients. Int J Men's Health 2010; 9: 3-25.
19. Rot I, Ogah I, Wassersug RJ,. The language of prostate cancer treatments and implications on informed decision making by patients and their partners. Eur J Cancer Care 2012; Epub ahead of print. May 11 2012.
20. Ogah I, Wassersug RJ,. How reliable are "reputable sources" for medical information on the internet?-The case of hormonal therapy to treat prostate cancer. Urol Oncol-Semin Ori 2012; in press.
21. Bekelman JE, Li Y, Gross CP,. Scope and impact of financial conflict of interest in biomedical research: a systematic review. JAMA 2003; 289: 454-64.
22. Friedberg M, Saffran B, Stinson TJ, Nelson W, Bennett CL,. Evaluation of conflict of interest in economic analyses of new drugs used in oncology. JAMA 1999; 282: 1453-7.
23. Kjaergard LL, Als-Nielsen B,. Association between competing interests and authors' conclusions: epidemiological study of randomized clinical trials published in the BMJ. BMJ 2002; 325: 1-4.
24. Ridker PM, Torres J,. Reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations: 2000-2005. JAMA 2006; 295: 2270-4.
25. Bhandari M, Busse JW, Jackowski D, et al., Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004; 170: 477-80.
26. Lexchin J, Bero LA, Djulbegovic B, Clark O,. Pharmaceutical industry sponsorship and research outcome quality: systematic review. BMJ 2003; 326: 1167-70.
27. Higano CS,. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003; 61: 32-8.
28. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J,. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 2004; 32: 40-50.
29. Mitchell S, Beck S, Hood L, Moore K, Tanner E,. Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment. Clin J Oncol Nurs 2007; 11: 99-113.
30. Howell D, Currie S, Mayo S, Jones G, Boyle M, Hack T, et al. A Pan-Canadian Clinical Practice Guideline: Assessment of Psychological Health Care Needs of the Adult Cancer Patient. Toronto: Cancer Partnership Against Cancer (Cancer Journey Action Group) and the Canadian Association of Psychological Oncology, 2009.
31. Portenoy R,. Cancer-related fatigue: an immense problem. Oncologist 2000; 5: 350-2.
32. Hewitt M, Greenfield S, Stovall E, eds. From Cancer Patient to Cancer Survivor: Lost in Translation. Washington: The National Academies Press, 2005.
33. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: Cancer-related fatigue (version 2). 2009. Available from: http://www.ons.org/Research/PEP/Topics/Fatigue(accessed Feb 2012).
34. Cooperburg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR,. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004; 22: 2141-9.
35. Soloway CT, Soloway MS, Kim SS, Kava BR,. Sexual, psychological and dyadic qualities of the prostate cancer "couple". BJU Int 2005; 95: 780-5.
36. Couper J, Bloch S, Love A, Macvean M, Duchesne GM, Kissane DW,. Psychosocial adjustment of female partners of men with prostate cancer: a review of the literature. Psychooncology 2006; 15: 937-53.
37. Couper J, Bloch S, Love A, Macvean M, Duchesne GM, Kissane DW,. The psychosocial impact of prostate cancer on patients and their partners. Med J Aust 2006; 185: 428-32.
38. Kim Y, Kashy DA, Wellisch DK, Spillers RL, Kaw CK, Smith TG,. Quality of life of couples dealing with cancer: dyadic and individual adjustment among breast and prostate cancer survivors and their spousal caregivers. Ann Behav Med 2008; 35: 230-8.
39. Sharifi N, Gulley JL, Dahut WL,. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010; 17: 305-15.
40. Singh J, Trabulsi EJ, Gomella LG,. The quality-of-life impact of prostate cancer treatments. Curr Urol Rep 2010; 11: 139-46.
41. Walker LM, Robinson JW,. A description of heterosexual couples' sexual adjustment to androgen deprivation therapy for prostate cancer. Psychooncology 2011; 20: 880-8.
42. Huggins C, Hodges CV,. Studies on prostatic cancer, I: the effect of estrogen and of androgen injection on serum phosphates in metastatic carcinoma of the prostate. Cancer Res J 1941; 1: 293-7.
43. Barry MJ, Delorenzo MA, Walker-Corkery ES, Lucas FL, Wennberg DC,. The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population based cohort study. BJU Int 2009; 98: 972-8.
44. Kuo Y, Goodwin JS, Shahinian VB,. Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer. BMC Health Serv Res 2008; 8: 146.
45. Murthy V, Norman AR, Barbachano Y, Parker CC, Dearnaley DP,. Long-term effects of a short course of neoadjuvant luteinizing hormone-releasing hormone analogue and radical radiotherapy on the hormonal profile in patients with localized prostate cancer. BJU Int 2007; 99: 1380-2.
46. Eldar-Geva T, Liberty G, Chertin B, et al., Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer. Eur J Endocrinol 2010; 162: 177-81.
47. Kornblith AB, Herr HW, Ofman US, Scher HI, Holland JC,. Quality of life of patients with prostate cancer and their spouses: the value of a data base in clinical care. Cancer 1994; 73: 2791-2802.
48. Hagedoorn M, Sanderman R, Bolks HN, Tuinstra J, Coyne JC,. Distress in couples coping with cancer: a meta-analysis and critical review of role and gender effects. Psychol Bull 2008; 134: 1-30.
49. Bishop MM, Beaumont JL, Hahn EA, et al., Late effects of cancer hematopoietic stem-cell transplantation on spouses or partners compared with survivors and survivor matched controls. J Clin Oncol 2007; 25: 1403-11.
50. Nakaya N, Saito-Nakaya K, Bidstrup PE, et al., Increased risk of severe depression in male partners of women with breast cancer. Cancer 2010; 116: 5527-34.
51. Sjövall K, Attner B, Lithman T, et al., Influence on the health of the partner affected by tumor disease in the wife or husband based on a population-based register study of cancer in Sweden. J Clin Oncol 2009; 27: 4781-6.
52. Baumgarten M,. The health of persons giving care to the demented elderly: a critical review of the literature. J Clin Epidemiol 1989; 42: 1137-48.
53. Grunfeld E, Coyle D, Whelan T, et al., Family caregiver burden: results of a longitudinal study of breast cancer patients and their principal caregivers. CMAJ 2004; 170: 1795-1801.
54. Chimonas S, Frosch Z, Rothman DJ,. From disclosure to transparency: the use of company payment data. Arch Intern Med 2011; 171: 81-6.
55. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS,. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005; 103: 1615-24.
56. Abel PD, Sundaram SK, Kynaston HG, et al., Cardiovascular events and clinical responses in prostate cancer patients treated with transcutaneous estrogen patches compared with LHRH analogues: results from a randomized phase II trial (MRC PR09 PATCH). J Clin Oncol 2011; 29 (Suppl. 7): Abstract 201.
57. Wibowo E, Schellhammer P, Wassersug RJ,. Role of estrogen in normal male function: clinical implications for patients with prostate cancer on androgen deprivation therapy. J Urol 2011; 185: 15-23.